A comprehensive, medically informed guide to the screenings that could save your life — and the unique factors LGBTQ+ adults need to consider when navigating preventive care.
Why This Guide Exists
If you are lesbian, gay, bisexual, transgender, queer, intersex, asexual, or anywhere else under the LGBTQ+ umbrella, the standard cancer screening conversation was not built with you in mind. Most national guidelines were developed from research on cisgender, heterosexual populations, and the result is a quiet but well-documented health gap: LGBTQ+ adults in the United States are statistically less likely to receive routine cancer screenings than their straight, cisgender peers, and many providers admit they were never trained on the nuances of caring for our community.
That gap matters. Cancer screening is one of the few medical interventions proven to reduce both how often people get certain cancers and how often they die from them. Catching cancer early — before symptoms appear — dramatically improves survival across nearly every common cancer type. And for LGBTQ+ adults specifically, several factors converge to make screening even more important: higher rates of tobacco and alcohol use in some subgroups, elevated HPV exposure depending on sexual practices, the long-term effects of gender-affirming hormone therapy, and a history of avoiding care because of discrimination or fear of being misgendered.
This guide breaks down what every U.S. LGBTQ+ adult should know about cancer screening in 2026: which tests to ask for, when to start, what they cost, how insurance coverage actually works under the Affordable Care Act, what changes if you are on hormones or have had gender-affirming surgery, and how to find a provider who will treat you with competence and respect. It is long. It is detailed. And it is meant to be the only screening conversation you need to read this year.
Before we go further, the standard disclaimer: this article is informational. It does not replace a real conversation with a real clinician who knows your personal and family medical history. But it should give you the vocabulary, confidence, and specific questions to make that conversation a productive one.
Part One: The Screening Disparity — Why LGBTQ+ Adults Are Falling Behind
Researchers have studied LGBTQ+ cancer screening rates extensively over the past decade, and the pattern is consistent. Sexual and gender minority adults in the United States are less likely than non-LGBTQ adults to be up to date with several routine cancer screenings. Bisexual women in particular show some of the lowest cervical screening rates, and transgender and gender-diverse adults attend cancer screening at recommended intervals less often than their cisgender peers across multiple cancer types.
The reasons are layered. Researchers have identified several recurring barriers:
Provider knowledge gaps. Many physicians and nurses report that their medical training did not cover the specific health needs of LGBTQ+ patients. They may not know whether a trans man with a cervix still needs a Pap test (he does), or whether a lesbian woman is at risk for HPV (she is), or how long-term estrogen therapy might affect a trans woman’s breast cancer screening schedule (it does, in important ways).
Heteronormative assumptions. Intake forms that only have “male” and “female” boxes. Mammography centers that turn away trans men because the system flags them as ineligible. Doctors who never ask about same-sex partners and therefore never discuss anal cancer screening. The cumulative effect is that LGBTQ+ patients have to do extra work in every clinical encounter just to be seen accurately.
History of medical mistreatment. Older LGBTQ+ adults remember a time when their identity was classified as a mental illness. Trans adults of every age can recount being misgendered, lectured, or refused care. That history creates avoidance, and avoidance creates missed screenings.
Insurance and cost barriers. While the Affordable Care Act requires most plans to cover preventive cancer screenings at no out-of-pocket cost, coverage gaps still exist for trans people whose insurance gendered designation does not match the body part being screened. A trans woman billed for a “female” mammogram on a “male” insurance record can find herself denied — even when she is medically eligible.
Risk factor concentration. LGBTQ+ adults, on average, have higher rates of tobacco use, higher rates of certain types of alcohol use, higher rates of HIV (particularly among gay and bisexual men and trans women), and higher exposure to chronic stress. Several of these factors also raise the underlying risk of specific cancers, which makes the lower screening rates more consequential, not less.
This guide cannot fix systemic problems. But it can equip you, as an individual patient, with enough specific information that you walk into the clinic knowing exactly what you need.
Part Two: The Core Cancer Screenings, Explained
The U.S. Preventive Services Task Force (USPSTF) is the most widely referenced authority on preventive screening in the United States, and under the Affordable Care Act, services it gives a grade of “A” or “B” must be covered by most insurance plans without cost-sharing. The American Cancer Society (ACS) publishes parallel guidelines that sometimes differ slightly. Below, I will reference both where relevant.
A note on language. Cancer screening recommendations are written around body parts and biology, not gender identity. If you have a cervix, you are at risk for cervical cancer, regardless of how you identify. If you have breast tissue — and almost everyone does, including many trans women on estrogen and most cis men — you have some level of breast cancer risk. The principle to remember: screen the organs you have.
Breast Cancer Screening
Breast cancer is the most commonly diagnosed cancer in U.S. women, and one of the leading causes of cancer death across the population. Mammography — a low-dose X-ray of the breast — is the primary screening tool.
Standard recommendation (USPSTF, 2024 update): Biennial screening mammography for women aged 40 to 74. The ACS recommends offering annual mammograms starting at 40, with women aged 45 to 54 strongly encouraged to screen annually, and biennial screening acceptable from 55 onward as long as health is good.
For cisgender lesbian, bisexual, and queer women: The recommendation is the same as for the general female population. Some studies suggest sexual minority women may have somewhat higher breast cancer risk factors — including lower rates of pregnancy and breastfeeding, and higher rates of alcohol use — but the screening guidelines themselves do not change. The action item is simply to make sure you are getting screened, which a meaningful portion of sexual minority women are not.
For trans women and nonbinary people assigned male at birth: This is one of the most important and least-discussed pieces of LGBTQ+ cancer screening. Long-term estrogen therapy creates real breast tissue and is associated with measurable breast cancer risk. Most expert guidance recommends that trans women on gender-affirming hormone therapy for five or more years follow the same breast cancer screening schedule as cisgender women — biennial mammography starting at age 40, or 50 depending on which guideline your provider follows. Some clinicians use additional criteria such as cumulative estrogen exposure and family history. If you are a trans woman, ask your provider directly: “Based on how long I have been on estrogen, when should I start mammography?”
For trans men and nonbinary people assigned female at birth: If you have not had top surgery, you have breast tissue, and you remain at risk. Standard recommendations apply: mammography starting at 40 (USPSTF) or by your individual risk schedule. If you have had top surgery, residual breast and chest wall tissue still carries some cancer risk, though it is reduced. Many surgeons and oncologists recommend periodic chest wall exams by a clinician after top surgery. The screening modality changes (mammography is rarely possible after mastectomy), but the screening conversation should not disappear.
Insurance note: Mammography is required to be covered without cost-sharing under the ACA for women aged 40+ (and earlier with risk factors). For trans patients, billing can be a headache. If you are denied coverage because of the gender marker on your insurance, the standard remedy is a clinician’s letter establishing medical necessity, plus a billing override code. Major LGBTQ+ health centers have staff who can help with these appeals.
Cervical Cancer Screening
Cervical cancer is overwhelmingly caused by persistent infection with high-risk strains of human papillomavirus (HPV). Screening — by Pap test (cervical cytology), HPV test, or both — has dramatically reduced cervical cancer mortality over the past several decades.
Standard recommendation: The ACS recommends that anyone with a cervix begin screening at age 25 and continue through 65. The preferred test is a primary HPV test every five years; alternatives include co-testing (HPV plus Pap) every five years or a Pap test alone every three years. The USPSTF recommends starting at age 21 with Pap testing every three years, and shifting to HPV-based testing options at age 30. After 65, most people with adequate prior screening can stop.
For lesbian, bisexual, and queer women: You need cervical cancer screening. This is one of the most pervasive myths in queer health: that women who have sex only with women do not need Pap tests. HPV is transmitted through skin-to-skin genital contact, oral sex, and shared sex toys — not just penetrative penis-in-vagina intercourse. Sexual minority women have measurable HPV prevalence and develop cervical cancer at rates that justify exactly the same screening schedule as straight women. Bisexual women, in the data, are particularly likely to fall behind on cervical screening, and the consequences are real.
For trans men and nonbinary people with a cervix: If you have a cervix, you need cervical cancer screening, full stop. Testosterone therapy can cause atrophic changes that sometimes make Pap tests harder to interpret (a higher rate of “unsatisfactory” results), so a clinician experienced in trans health can help — sometimes by pre-treating with topical estrogen briefly to improve cell collection. The newer HPV self-collection options, which the FDA approved in 2024 and the ACS endorsed in 2025, are a meaningful advance: a swab can be self-collected in a private setting, which removes one of the most distressing parts of the screening experience for many trans men.
For trans women: If you have not had vaginoplasty, this section does not apply to you. If you have had vaginoplasty, the neovagina is not made of cervical tissue and does not require Pap testing in the same way. However, the neovagina can develop other concerns (HPV-related lesions, particularly if penile/scrotal skin was used) and should be examined periodically by a clinician experienced in post-vaginoplasty care.
HPV vaccination: Regardless of where you are in life, if you have not been vaccinated against HPV, talk to a clinician. The vaccine is routinely recommended for everyone ages 9 to 26, and shared decision-making for vaccination is recommended through age 45. It prevents not just cervical cancer but also anal, oropharyngeal, vulvar, vaginal, and penile cancers — all relevant across LGBTQ+ populations.
Colorectal Cancer Screening
Colorectal cancer rates are rising in younger adults across the United States, and current guidelines reflect that.
Standard recommendation: Both the USPSTF and ACS recommend starting screening at age 45 for adults at average risk and continuing through age 75. From 76 to 85, screening is a shared decision between you and your provider. After 85, routine screening is generally not recommended.
You have options. Colonoscopy every 10 years is the most thorough single test. Other accepted approaches include flexible sigmoidoscopy every five years, CT colonography every five years, fecal immunochemical testing (FIT) every year, multi-target stool DNA testing (Cologuard) every one to three years, and a few less-common alternatives. Any approved test you will actually complete is far better than the perfect test you skip.
For LGBTQ+ adults specifically: The guidelines are the same. The disparity to be aware of is that colorectal cancer screening rates are lower in LGBTQ+ populations, and clinical research has begun to focus specifically on closing that gap. If you are 45 or older and have never been screened, this is a high-priority action item.
Risk factors that may move you to earlier screening: A first-degree relative (parent, sibling, child) diagnosed with colorectal cancer or advanced polyps; a personal history of inflammatory bowel disease; certain hereditary syndromes such as Lynch syndrome. Discuss family history in detail with your clinician — many people do not realize that a parent’s “colon polyp” diagnosis is relevant information.
Lung Cancer Screening
Lung cancer remains the leading cause of cancer death in the United States. The good news: low-dose CT screening, when done correctly in eligible adults, reduces lung cancer mortality.
Standard recommendation (USPSTF): Annual low-dose computed tomography (LDCT) for adults aged 50 to 80 who have a 20 pack-year or greater smoking history and who currently smoke or have quit within the past 15 years. A “pack-year” equals smoking one pack per day for one year (so 10 years of two-packs-per-day equals 20 pack-years, as does 20 years of one-pack-per-day).
For LGBTQ+ adults specifically: Smoking rates have historically been higher in lesbian, gay, bisexual, and transgender populations than in the general adult population, with some recent narrowing of the gap. That elevated baseline rate means more LGBTQ+ adults are eligible for lung cancer screening — and a meaningful number do not realize it. If you are 50 or older with a smoking history, ask your primary care provider whether you qualify for annual LDCT screening. This is one of the most underused high-impact preventive services in our community.
If you currently smoke, quitting is the single most impactful thing you can do for your cancer risk, full stop — more than any individual screening. Modern smoking cessation tools include nicotine replacement therapy, varenicline, bupropion, and behavioral counseling, and most are covered without cost-sharing under ACA preventive benefits.
Prostate Cancer Screening
Prostate cancer screening is more complicated than the others. The benefits are real, but so are the harms — overdiagnosis, overtreatment, incontinence, sexual dysfunction — and the major guideline bodies emphasize informed, shared decision-making rather than blanket screening.
Standard recommendation (USPSTF): For men aged 55 to 69, the decision to undergo periodic PSA-based screening should be an individual one, made after a detailed conversation about benefits and harms. For men 70 and older, routine PSA screening is not recommended. The ACS recommends a conversation at age 50 for average-risk men, age 45 for men at higher risk (including Black men and those with a first-degree relative diagnosed before age 65), and age 40 for men with multiple first-degree relatives diagnosed at younger ages.
For gay, bisexual, and queer men: The clinical recommendations are identical. The thing worth knowing is that prostate cancer treatment — especially surgery and radiation — can affect sexual function in ways that may matter differently to gay men than the heterosexual men most clinical research has centered. Receptive anal intercourse, for example, can be affected after pelvic radiation or surgery in ways that providers may not proactively discuss. If you are weighing prostate cancer treatment, finding a urologist or oncologist familiar with LGBTQ+ patients can make a substantial difference in the quality of the conversation.
For trans women: If you have not had genital surgery, you have a prostate and the screening conversation applies to you. Long-term estrogen therapy lowers prostate cancer risk overall, but does not eliminate it. PSA values tend to be lower on estrogen, so the standard cutoffs used to flag concern may not apply directly — an experienced provider should interpret your results in context. If you have had vaginoplasty, the prostate is typically retained and remains a screening consideration.
For trans men: This section does not apply to you.
Anal Cancer Screening
Anal cancer is a particularly important conversation for gay and bisexual men, men who have sex with men more broadly, trans women, and anyone living with HIV — all groups at elevated risk due to HPV exposure patterns and, in the case of people with HIV, immune system effects on viral clearance.
The state of guidelines: For decades there were no national guidelines for anal cancer screening. The landmark ANCHOR trial, published in 2022, changed that by showing that treating anal high-grade squamous intraepithelial lesions (HSIL) substantially reduces the likelihood of progression to invasive anal cancer. Following that result, the International Anal Neoplasia Society and the U.S. Department of Health and Human Services both released consensus guidelines in 2024.
Current recommendations (HHS/IANS 2024): For people living with HIV, anal cancer screening is recommended starting at age 35 for gay and bisexual men and trans women, and starting at age 45 for other people with HIV. Screening combines anal cytology (a swab analogous to a cervical Pap), high-risk HPV testing, and — where abnormalities are found — high-resolution anoscopy (HRA), a magnified examination of the anal canal.
For HIV-negative gay and bisexual men: No formal national guidelines yet recommend routine anal screening. Many specialists offer anal cytology to higher-risk patients — particularly those with a history of receptive anal sex, HPV exposure, or anal warts — as part of shared decision-making. The American Cancer Society notes that some experts suggest screening with digital rectal exam and anal cytology for those at higher risk.
Practical advice: If you are a gay, bisexual, or queer man living with HIV, or a trans woman living with HIV, ask your HIV provider directly about anal cancer screening based on the new 2024 guidelines. If you are HIV-negative but engage in receptive anal sex, ask your primary care provider whether anal cytology makes sense for you. Be aware that access to high-resolution anoscopy — the follow-up test if cytology is abnormal — is uneven across the country, with most experienced providers concentrated in urban LGBTQ+ health centers.
Skin Cancer
Skin cancer is the most common cancer in the United States. The USPSTF gives a less directive recommendation here — the evidence for screening asymptomatic adults is mixed — but most dermatologists recommend an annual full-body skin exam, particularly for adults with significant sun exposure, fair skin, family history of melanoma, or many moles.
For LGBTQ+ adults specifically: Several studies have found higher rates of indoor tanning bed use among gay and bisexual men, which is a known risk factor for melanoma. If you have used tanning beds, have substantial sun exposure history, or notice a new or changing mole, get a dermatology consult. The “ABCDE” mole criteria are worth memorizing: Asymmetry, Border irregularity, Color variation, Diameter over 6mm, and Evolution (change over time).
Liver Cancer
For people living with hepatitis B or hepatitis C, or with cirrhosis from any cause, liver cancer screening — typically ultrasound every six months, sometimes with alpha-fetoprotein blood testing — is recommended. This is relevant in the LGBTQ+ community because of historically higher rates of hepatitis B and C, particularly among gay and bisexual men and people with a history of injection drug use. If you have ever had hepatitis B or C, ask your provider about a hepatology consult.
Oral and Oropharyngeal Cancer
There is no formal screening test for oral and oropharyngeal cancers, but dentists routinely screen with visual examination during cleanings. HPV-related oropharyngeal cancers (which involve the base of the tongue and tonsils) have risen substantially over the past two decades, driven by oral HPV transmission. Vaccination is the primary prevention, and regular dental care matters. If you have not seen a dentist recently, that is a screening visit too.
Part Three: Special Considerations by Identity
Lesbian, Bisexual, and Queer Women
The biggest screening gaps for cis sexual minority women tend to be cervical cancer and breast cancer screening. The myths to discard:
- “I do not have sex with men, so I do not need Pap tests.” False. HPV transmits between women, and cervical cancer risk persists.
- “I do not need a mammogram unless I have a family history.” False. Most breast cancers occur in women without a family history.
- “My doctor will tell me when I need a screening.” Sometimes true, often not, and especially unreliable if your doctor does not know you are queer or assumes screening guidelines do not apply to you.
Higher rates of nulliparity (never giving birth) and lower rates of breastfeeding in sexual minority women are associated with slightly elevated baseline breast cancer risk. Higher rates of obesity and alcohol use in some subgroups compound this. None of it changes the screening schedule, but all of it raises the importance of actually following it.
Gay, Bisexual, and Queer Men
Two screenings deserve particular attention: anal cancer screening (especially if living with HIV) and lung cancer screening (given historically elevated smoking rates). Add to that the importance of HPV vaccination through age 45 if not previously vaccinated, regular HIV testing, and STI screening that includes oropharyngeal and rectal sites — not just urethral — for accurate detection.
Prostate cancer treatment decisions deserve more careful conversation than the typical urology clinic offers, particularly around sexual function and quality of life.
Transgender Women
Three priorities. First, breast cancer screening with mammography after several years on estrogen — typically starting at 40 or 50 depending on your provider and cumulative hormone exposure. Second, prostate cancer screening conversations starting at the age recommended for cis men, with the awareness that PSA interpretation may need to be adjusted for hormone effects. Third, anal cancer screening if living with HIV, particularly starting at age 35 under the 2024 HHS guidelines.
If you have had vaginoplasty, find a clinician familiar with neovaginal care for periodic examination. The neovagina has its own anatomy and its own potential concerns, and routine pelvic exams designed for cis women do not transfer directly.
Transgender Men and Nonbinary People Assigned Female at Birth
Cervical cancer screening if you have a cervix. Breast cancer screening if you have breast tissue and meet age criteria. If you have had top surgery, periodic chest wall exams. Standard colorectal cancer screening starting at 45. Be aware that testosterone can produce atrophic vaginal changes that complicate Pap testing — a clinician experienced in trans care can help, and self-collected HPV testing is an increasingly available alternative.
The single biggest barrier is access. Many trans men have stopped seeing gynecologists entirely because of repeated misgendering, intake forms that do not fit, and clinicians who do not understand the body before them. LGBTQ+ community health centers (Fenway in Boston, Callen-Lorde in New York, Lyon-Martin in San Francisco, Whitman-Walker in Washington D.C., Howard Brown in Chicago, and dozens of others nationally) have specifically built welcoming gynecological care for trans patients.
Nonbinary and Genderqueer Adults
Apply the screening guidelines that match the organs you have. Bring this article, or print the relevant sections, and have a frank conversation with a clinician about which screenings apply to your specific anatomy. You are entitled to that conversation, and a good clinician will welcome it.
Intersex Adults
Cancer screening for intersex adults depends heavily on individual anatomy, hormonal history, and any prior surgeries (some of which may have been performed in childhood without informed consent). Specialty centers focused on intersex health, such as the InterACT advocacy network and certain academic endocrinology programs, can help develop an individualized plan.
People Living with HIV
HIV is associated with elevated risk for several cancers, including anal cancer, certain lymphomas, Kaposi sarcoma, cervical cancer, lung cancer, and liver cancer (especially with hepatitis co-infection). The 2024 HHS guidelines on anal cancer screening for people with HIV are a major addition to standard care. Your HIV provider should be coordinating cancer screening as part of overall management; if not, ask directly.
Older LGBTQ+ Adults
The conversation shifts after roughly age 65 or 75, when several screenings have natural stopping points based on declining benefit and rising harms. Continued screening into older age can still make sense for healthy adults with long life expectancy, but most guideline bodies recommend stopping cervical screening at 65 (with adequate prior screening), colorectal screening at 75 to 85 based on shared decision, mammography somewhere around 74 to 75, and lung cancer screening at 80. These are starting points for conversation, not hard cutoffs.
Part Four: Insurance, Cost, and Access
What the Affordable Care Act Covers
Under the ACA, most private health insurance plans and Medicaid expansion plans must cover USPSTF Grade A and B preventive services without cost-sharing. That includes mammography, cervical cancer screening, colorectal cancer screening, lung cancer screening for eligible adults, HPV vaccination through age 26 (and shared decision-making to age 45), and counseling on tobacco cessation, alcohol use, and HIV prevention.
“Without cost-sharing” means no copay, no coinsurance, and no deductible — as long as the test is done as a screening for an average-risk patient at an in-network provider. The fine print where coverage breaks down:
- A screening colonoscopy that finds and removes a polyp may be reclassified as diagnostic and billed differently. The ACA has been clarified to require coverage even when polyps are removed, but billing departments still mess this up. Verify before scheduling.
- Repeat tests after an abnormal result may not be covered the same way.
- Out-of-network providers can balance bill.
- Short-term limited duration plans and certain religious cost-sharing arrangements are not subject to the same requirements.
For trans patients, the additional complication is gender-marker mismatches. Insurance companies are increasingly required, under federal nondiscrimination rules, to cover medically necessary screenings regardless of gender marker, but you may need to actively work with billing to get this resolved.
If You Are Uninsured
The CDC’s National Breast and Cervical Cancer Early Detection Program provides free or low-cost mammograms and cervical cancer screening for uninsured and underinsured women who meet income criteria — and most programs serve trans women and trans men with relevant anatomy. Federally Qualified Health Centers (FQHCs) provide sliding-scale care including preventive cancer screening regardless of insurance status. Local LGBTQ+ community health centers often have dedicated patient navigators who can help connect you to free or low-cost screening.
Finding LGBTQ+-Competent Providers
A few starting points:
- GLMA: Health Professionals Advancing LGBTQ+ Equality maintains a national directory of LGBTQ+-affirming healthcare providers.
- The National LGBT Cancer Network has a directory of welcoming cancer screening and treatment providers.
- Out2Enroll helps LGBTQ+ adults navigate ACA marketplace coverage.
- OutCare Health lists trained, vetted LGBTQ+-affirming clinicians by location.
- Community health centers in the Fenway Institute affiliate network, Howard Brown Health network, and similar LGBTQ+-specific systems offer culturally competent care.
When you contact a new provider, it is reasonable to ask: “Do you have experience caring for LGBTQ+ patients?” or, more specifically, “Have you done Pap tests on trans men before?” or “Do you have experience with breast cancer screening for trans women on long-term estrogen?” The answers tell you a great deal.
Part Five: A Practical Action Checklist
Here is a concrete sequence to put this guide into action.
This month:
- Identify your primary care provider. If you do not have one, find one through the resources above.
- Schedule a comprehensive preventive visit if you have not had one in over a year.
- Pull together your family cancer history — parents, siblings, grandparents — to bring to the visit.
- Make a list of all the screenings this guide suggests apply to your anatomy and risk profile.
At the visit:
- Disclose your sexual orientation and gender identity if you feel safe doing so. It changes the relevance of several recommendations.
- Discuss your sexual practices, accurately, including which kinds of sex you have. This affects HPV exposure and anal cancer screening conversations.
- Confirm your HPV vaccination status and discuss catch-up vaccination if you are under 46 and unvaccinated.
- Ask about every screening relevant to your anatomy. Use the list you brought.
- Confirm which screenings are covered without cost-sharing under your insurance.
- Schedule any screenings you are due for before you leave.
Ongoing:
- Set calendar reminders for repeat screening intervals — most are annual, every two to three years, or every five years.
- If you have HIV, integrate cancer screening into your HIV care visits.
- If you are on long-term gender-affirming hormone therapy, revisit your screening schedule annually with your provider as your hormonal exposure accumulates.
- Pay attention to your body. If something changes — a lump, persistent bleeding, persistent cough, blood in the stool, a new or changing mole, unexplained weight loss — get it evaluated promptly, regardless of where you are in your screening schedule.
Part Six: The Bigger Picture
There is a thread that runs through every section of this guide: cancer screening for LGBTQ+ adults has historically been an afterthought, and a small but determined community of researchers, clinicians, and advocates has spent the past decade pushing it from afterthought toward standard of care. Real progress has happened. The 2024 anal cancer screening guidelines for people with HIV represent the first national framework for a cancer that disproportionately affects gay and bisexual men and trans women. The 2025 ACS endorsement of self-collected HPV testing creates a path to cervical screening that does not require an invasive pelvic exam. Gender-affirming care has matured enough that experienced providers can now offer nuanced screening recommendations for trans patients based on years of accumulated clinical experience.
What has not changed quickly enough is the day-to-day experience of being an LGBTQ+ patient in a clinic that was not designed for you. The screening rates are improving, but they are still lower than they should be. The provider knowledge gap is closing, but it is still wide. The insurance and billing systems still produce maddening glitches that disproportionately affect trans patients in particular.
The way forward is partly systemic — better training for clinicians, better data collection, better insurance policy — and partly individual. The individual part is this: you are the most consistent advocate you will ever have inside the healthcare system. You can show up informed, ask specific questions, and decline to accept care that does not fit your actual body and life. Every time an LGBTQ+ patient walks into a clinic and asks the right screening question, a small piece of the system gets pushed forward.
Cancer screening is not glamorous. It is the unsexy backbone of cancer mortality reduction over the past fifty years. Showing up for routine, evidence-based screening — on the right schedule, for the body you actually have — is one of the most consequential things you can do for your long-term health. The data are clear that as a community we are not yet doing it as well as our straight, cisgender peers, and the consequences of that gap accrue in the form of later-stage diagnoses and worse outcomes.
You can change your part of that pattern. The next step is a phone call to make an appointment.
This article is for general informational purposes and does not constitute medical advice. Always consult a qualified healthcare professional for individualized recommendations. Screening guidelines are updated periodically; verify with your provider that the recommendations cited here remain current at the time of your visit.
Sources and further reading: U.S. Preventive Services Task Force (uspreventiveservicestaskforce.org), American Cancer Society Cancer Screening Guidelines (cancer.org), HHS Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV (2024 update), International Anal Neoplasia Society Consensus Guidelines (2024), National LGBT Cancer Network (cancer-network.org), GLMA Health Professionals Advancing LGBTQ+ Equality (glma.org), Fenway Institute (fenwayhealth.org), the ANCHOR Study (NEJM, 2022), and peer-reviewed reviews of LGBTQ+ cancer screening disparities published in Oncology Nursing Forum, Journal of Clinical Oncology, and The Lancet eClinicalMedicine.
